

=> d his

(FILE 'HOME' ENTERED AT 06:51:22 ON 27 AUG 2002)
 SET COST OFF

FILE 'HCAPLUS' ENTERED AT 06:51:50 ON 27 AUG 2002

E RATH M/AU
 L1 62 S E3-E7, E14, E15
 L2 8 S L1 AND (?CHOLESTER? OR ?LIPOPROTEIN?)
 E US2000-237186/AP, PRN
 L3 1 S E5
 E WO2001-US31203/AP, PRN
 L4 1 S E3
 L5 1 S L3, L4
 L6 1 S L1, L2 AND L5
 SEL RN

FILE 'REGISTRY' ENTERED AT 06:55:51 ON 27 AUG 2002

L7 44 S E1-E44
 L8 3 S 50-81-7 OR 10504-35-5 OR 62624-30-0
 L9 845 S (50-81-7 OR 10504-35-5 OR 62624-30-0) /CRN
 L10 1 S L7 AND L8
 L11 2 S L7 AND L9
 L12 4 S L7 AND OC4/ES
 L13 7 S L9 AND (CA OR MG) /ELS AND 2/NC NOT (IDS OR MXS OR PMS OR MNS)
 L14 5 S L13 NOT (45CA OR KAPPA)
 L15 840 S L9 NOT L8, L10-L12, L14
 L16 28 S C22H38O7/MF AND OC4/ES
 L17 15 S L16 AND ASCORBIC ACID
 L18 7 S L17 AND 6
 L19 6 S L18 AND 1/NR
 L20 4 S L19 AND HEXADECANOATE
 L21 2 S L20 NOT (ION OR GAMMA)
 L22 2 S 59-67-6 OR 98-92-0
 L23 824 S (59-67-6 OR 98-92-0) /CRN
 L24 2 S L7 AND L22, L23
 L25 3 S 56-87-1 OR 923-27-3 OR 70-54-2
 L26 2112 S (56-87-1 OR 923-27-3 OR 70-54-2) /CRN
 L27 2 S L7 AND L25, L26
 L28 3 S 147-85-3 OR 344-25-2 OR 609-36-9
 L29 229 S (147-85-3 OR 344-25-2 OR 609-36-9) /CRN
 L30 2 S L7 AND L28, L29
 L31 34 S L7 NOT L8, L10, L11, L12, L14, L21, L22, L24, L25, L27, L28, L30
 L32 1 S 57-88-5
 L33 1 S 6027-13-0
 L34 2 S (D-HOMOCYSTEINE OR DL-HOMOCYSTEINE) /CN
 L35 32 S L31 NOT L32-L34
 L36 1 S (.BETA.-TOCOPHEROL) /CN
 L37 1 S (.GAMMA.-TOCOPHEROL) /CN
 L38 1 S (.DELTA.-TOCOPHEROL) /CN
 L39 1 S .BETA.-CAROTENE/CN
 L40 1 S BIOTIN/CN
 L41 1 S CALCIUM GLYCINATE/CN
 L42 1 S COENZYME Q10/CN
 L43 1 S COPPER GLYCINATE/CN
 L44 1 S CYANOCOBALAMIN/CN
 L45 1 S D-.ALPHA.-TOCOPHEROL/CN
 L46 1 S CALCIUM PANTOTHENATE/CN
 L47 5 S 79-83-4/CRN AND CA/ELS AND 2/NC
 L48 3 S L47 NOT (MXS OR IDS) /CI
 L49 1 S DICALCIUM PHOSPHATE/CN
 L50 1 S FOLIC ACID/CN
 L51 2 S INOSITOL/CN

5
 Jan Delaval
 Reference Librarian
 Biotechnology & Chemical Library
 CM1 1E07 - 703-308-4498
 jan.delaval@uspto.gov

L52 1 S L-ARGININE/CN
 L53 1 S L-CARNITINE/CN
 L54 1 S L-CYSTEINE/CN
 L55 1 S L-SELENOMETHIONINE/CN
 L56 13 S 7664-38-2/CRN AND CA/ELS AND 2/NC NOT (IDS OR PMS OR MNS OR M
 L57 12 S L56 NOT 45CA
 L58 1 S L31 AND MG/ELS
 L59 1 S PYCNOGENOL/CN
 L60 1 S PYRIDOXINE/CN
 L61 1 S RIBOFLAVIN/CN
 L62 1 S THIAMINE/CN
 L63 1 S ZINC GLYCINATE/CN
 L64 0 S (148-03-8 AND 7616-22-0 AND 119-13-1) /CRN
 L65 38 S L36-L46, L48-L55, L57-L63
 L66 9 S L35 NOT L65
 SEL RN 1 6 8
 L67 3 S E45-E47
 L68 2 S C4H8CRN2O4/MF
 L69 1 S C4H8MGN2O4/MF
 L70 0 S C4H8MON2O4/MF
 L71 6 S C4H8N2O4ZN/MF
 L72 1 S GLYCINE/CN
 L73 1 S C4H8CAN2O4/MF
 L74 41 S 56-40-6/CRN AND (CA OR CR OR CU OR MG OR MO OR ZN) /ELS
 L75 11 S L74 AND 2/NC
 L76 4 S L75 NOT (CL/ELS OR COMPD)
 L77 24 S C4H8CUN2O4/MF
 L78 17 S L77 AND GLYCIN?
 L79 15 S L78 AND 2/NR
 L80 11 S L79 NOT D/ELS
 SEL RN 1 6 9 10 11
 L81 5 S E48-E52
 L82 55 S L65, L67-L69, L71, L73, L76, L81
 L83 6 S L66 NOT L82
 L84 1 S L83 AND C6/ES
 L85 4 S L83 NOT L72, L84

FILE 'HCAPLUS' ENTERED AT 07:34:44 ON 27 AUG 2002

L86 46509 S L8, L10, L11, L12, L14, L21
 L87 90884 S ASCORBIC ACID OR VITAMIN(S) C
 L88 94543 S L86, L87
 L89 3119 S L15
 L90 95752 S L88, L89
 L91 13273 S L22 OR L24
 L92 35062 S NICOTINIC ACID OR NIACIN AMIDE OR NIACINAMIDE OR NIACIN OR VI
 761 S 3 PYRIDINECARBOXAMIDE OR PYRIDINE 3 CARBOXYLIC ACID
 L94 882 S 3 PYRIDINECARBOXYLIC ACID
 L95 7 S 3 AMINOCARBONYLPYRIDINE
 L96 20 S 3 CARBAMOYLPYRIDINE
 L97 9 S 3 AMIDOPYRIDINE
 L98 53 S 3 PYRIDINE CARBOXYLIC ACID
 L99 1250 S L23
 L100 38515 S L91-L99
 L101 35891 S L25 OR L27
 L102 9829 S L26
 L103 86562 S LYSINE
 L104 93564 S L101-L103
 L105 22331 S L29 OR L30
 L106 758 S L29
 L107 53725 S PROLINE
 L108 57057 S L105-L107
 L109 118 S L90 AND L100 AND L104 AND L108
 L110 118 S (L90 OR ASCORB?) AND L100 AND L104 AND L108

L111 118 S L109, L110
 L112 90 S L111 AND L72
 L113 38 S L112 AND L85
 L114 97 S L111 AND L82
 L115 118 S L111-L114

FILE 'REGISTRY' ENTERED AT 07:47:07 ON 27 AUG 2002
 L116 1 S CITRIC ACID/CN
 L117 6607 S 77-92-9/CRN
 L118 4998 S L117 AND 2/NC NOT (MXS OR MNS OR IDS OR PMS)/CI
 L119 4920 S L118 NOT COMPD
 L120 4416 S L119 AND NR>=1
 L121 504 S L119 NOT L120

FILE 'HCAPLUS' ENTERED AT 07:48:36 ON 27 AUG 2002
 L122 27 S L116, L121 AND L111
 L123 118 S L115, L122
 L124 3 S L1 AND L123
 L125 34 S L123 AND PHARMACEUT?/SC, SX
 L126 17 S L123 AND PHARMACOL?/SC, SX
 L127 55 S L123 AND (FOOD? OR NUTRI? OR FEED?)/SC, SX
 L128 3 S L6, L124 AND L125-L127
 L129 78 S L125-L127 NOT L128
 L130 37 S L123 NOT L128, L129
 L131 13 S L129 AND (L32 OR ?CHOLESTER?)
 L132 1 S L129 AND (L33 OR L34 OR HOMOCYST?)
 L133 1 S L129 AND (LIPOPROTEIN? OR LPA OR LP A)
 L134 2 S L129 AND TRIGLYCER?
 L135 0 S L129 AND LDL
 L136 0 S L129 AND LOW DENSITY (S) LIPOPROTEIN
 L137 0 S L129 AND LOW DN (S) LIPOPROTEIN
 L138 0 S L129 AND LOW DEN? (S) LIPOPROTEIN
 L139 0 S L129 AND LOW D (S) LIPOPROTEIN
 L140 0 S L129 AND LOW D (L) LIPOPROTEIN
 L141 16 S L131-L134
 L142 62 S L129 NOT L131-L141
 L143 3 S L128 AND L1-L6, L86-L115, L122-L142

=> fil hcaplus
 FILE 'HCAPLUS' ENTERED AT 08:10:21 ON 27 AUG 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Aug 2002 VOL 137 ISS 9
 FILE LAST UPDATED: 25 Aug 2002 (20020825/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For

information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d all tot 1143

L143 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2002 ACS

AN 2002:275779 HCAPLUS

DN 136:299733

TI Compositions for lowering plasma **lipoprotein** (A) and risk factors of cardiovascular diseases

IN Rath, Matthias

PA USA

SO PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-00

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002028379	A2	20020411	WO 2001-US31203	20011003 <--
	W: AE, AG, AL, AM, AT, AU, AZ, CO, CR, CU, CZ, DE, DK, DM, GM, HR, HU, ID, IL, IN, IS, LS, LT, LU, LV, MA, MD, MG, RO, RU, SD, SE, SG, SI, SK, VN, YU, ZA, ZW, AM, AZ, BY, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			BA, BB, BG, BR, BY, BZ, CA, CH, CN, DZ, EC, EE, ES, FI, GB, GD, GE, GH, JP, KE, KG, KP, KR, KZ, LC, LK, LR, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, KG, KZ, MD, RU, TJ, TM	
	US 2002094996	A1	20020718	US 2001-970609	20011003 <--

PRAI US 2000-237186P P 20001003 <--

AB The present invention provides compns. and methods for lowering plasma Lp(A) levels in humans. The present invention provides compns. and methods for lowering the risk factors for cardiovascular diseases. Moreover, this invention provides therapeutic alternatives to current pharmaceutical (e.g., **ascorbic acid, niacin**) interventions for the lowering of **cholesterol, LDL-cholesterol, triglycerides** and other metabolic risk factors. Thus, **ascorbic acid** can be used at 1580 mg, and **niacin** at 60 mg.

ST **lipoprotein plasma lowering ascorbate niacin**

IT **Lipoproteins**

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Lp(a); compns. for lowering plasma **lipoprotein** and risk factors of cardiovascular diseases)

IT **Flavonoids**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (biflavonoids; compns. for lowering plasma **lipoprotein** and risk factors of cardiovascular diseases)

IT **Anticholesteremic agents**

(compns. for lowering plasma **lipoprotein** and risk factors of cardiovascular diseases)

IT **Glycerides, biological studies**

RL: BSU (Biological study, unclassified); BIOL (Biological study) (compns. for lowering plasma **lipoprotein** and risk factors of cardiovascular diseases)

IT **Carotenes, biological studies**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. for lowering plasma **lipoprotein** and risk factors of cardiovascular diseases)

IT Human
(compns. for lowering plasma **lipoprotein(a)** and risk factors of cardiovascular diseases)

IT Cardiovascular system
(disease; compns. for lowering plasma **lipoprotein** and risk factors of cardiovascular diseases)

IT Drug delivery systems
(infusions; compns. for lowering plasma **lipoprotein** and risk factors of cardiovascular diseases)

IT Drug delivery systems
(inhalants; compns. for lowering plasma **lipoprotein** and risk factors of cardiovascular diseases)

IT Drug delivery systems
(injections; compns. for lowering plasma **lipoprotein** and risk factors of cardiovascular diseases)

IT **Lipoproteins**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(low-d.; compns. for lowering plasma **lipoprotein** and risk factors of cardiovascular diseases)

IT Drug delivery systems
(suppositories; compns. for lowering plasma **lipoprotein** and risk factors of cardiovascular diseases)

IT Drug delivery systems
(tablets; compns. for lowering plasma **lipoprotein** and risk factors of cardiovascular diseases)

IT 57-88-5, **Cholesterol**, biological studies 6027-13-0,
Homocysteine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(compns. for lowering plasma **lipoprotein** and risk factors of cardiovascular diseases)

IT 50-81-7, **Ascorbic acid**, biological studies
52-90-4, **L-Cysteine**, biological studies 56-40-6D,
Glycine, chromium complexes 56-87-1, **Lysine**,
biological studies 58-85-5, **Biotin** 59-02-9,
D-.alpha.-Tocopherol 59-30-3, **Folic acid**, biological studies
59-43-8, **Thiamine**, biological studies 59-67-6,
Nicotinic acid, biological studies 65-23-6,
Pyridoxine 67-97-0, **Cholecalciferol** 68-19-9,
Cyanocobalamin 74-79-3, **L-Arginine**, biological studies
83-88-5, **Riboflavin**, biological studies 87-89-8,
Inositol 98-92-0, **Niacinamide** 119-13-1,
.delta.-**Tocopherol** 127-40-2, **Lutein** 137-08-6 137-66-6
, **L-Ascorbyl palmitate** 147-85-3, **L-Proline**,
biological studies 148-03-8, .beta.-**Tocopherol** 303-98-0
, **Coenzyme Q10** 432-70-2, .alpha.-**Carotene** 541-15-1,
L-Carnitine 657-27-2, **L-Lysine** hydrochloride
3211-76-5, **L-Selenomethionine** 5743-27-1, **Calcium Ascorbate** 7235-40-7, .beta.-**Carotene** 7439-96-5D
, **Manganese**, chelates 7439-98-7D, **Molybdenum**, **glycine complexes** 7440-09-7D, **Potassium**, chelates 7440-47-3D, **Chromium**, **glycine complexes** 7616-22-0, .gamma.-**Tocopherol** 7757-93-9, **Dicalcium phosphate** 7776-34-3, **L-Proline** hydrochloride 13479-54-4, **Copper glycinate** 14281-83-5, **Zinc glycinate** 14783-68-7 15431-40-0
, **Magnesium ascorbate** 35947-07-0, **Calcium glycinate** 174882-69-0, **Pycnogenol**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for lowering plasma **lipoprotein** and risk factors of cardiovascular diseases)

L143 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2002 ACS

AN 2002:272794 HCAPLUS

DN 136:299725

TI Therapeutic combination of ascorbate with lysine or arginine for prevention and treatment of cancer

IN Rath, Matthias

PA Neth.

SO Eur. Pat. Appl., 12 pp.

CODEN: EPXXDW

DT Patent

LA English

IC ICM A61K031-195

ICS A61K031-375; A61P035-00

ICI A61K031-195, A61K031-375

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	<u>EP 1195159</u>	<u>A1</u>	<u>20020410</u>	EP 2000-121950	20001009
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

AB A therapeutic compn. for the prevention and treatment of different forms of cancer in very elevated dosages of ascorbic acid and salts, L-Lysine and L-proline, vitamins and trace elements.

ST therapeutic combination ascorbate lysine antitumor; arginine ascorbate antitumor therapeutic combination

IT Flavonoids

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biflavonoids; therapeutic combination of ascorbate with lysine or arginine for prevention and treatment of cancer)

IT Uterus, neoplasm

(cervix, inhibitors; therapeutic combination of ascorbate with lysine or arginine for prevention and treatment of cancer)

IT Antitumor agents

(cervix; therapeutic combination of ascorbate with lysine or arginine for prevention and treatment of cancer)

IT Intestine, neoplasm

(duodenum, inhibitors; therapeutic combination of ascorbate with lysine or arginine for prevention and treatment of cancer)

IT Antitumor agents

(duodenum; therapeutic combination of ascorbate with lysine or arginine for prevention and treatment of cancer)

IT Antitumor agents

(esophagus; therapeutic combination of ascorbate with lysine or arginine for prevention and treatment of cancer)

IT Drug delivery systems

(inhalants; therapeutic combination of ascorbate with lysine or arginine for prevention and treatment of cancer)

IT Lung, neoplasm

Ovary, neoplasm

Skin, neoplasm

Stomach, neoplasm

Testis, neoplasm

(inhibitors; therapeutic combination of ascorbate with lysine or arginine for prevention and treatment of cancer)

IT Drug delivery systems

(injections; therapeutic combination of ascorbate with lysine or arginine for prevention and treatment of cancer)

IT Antitumor agents
(lung; therapeutic combination of **ascorbate** with
lysine or arginine for prevention and treatment of cancer)

IT Antitumor agents
(mammary gland; therapeutic combination of **ascorbate** with
lysine or arginine for prevention and treatment of cancer)

IT Antitumor agents
(melanoma; therapeutic combination of **ascorbate** with
lysine or arginine for prevention and treatment of cancer)

IT Esophagus
Mammary gland
(neoplasm, inhibitors; therapeutic combination of **ascorbate**
with **lysine** or arginine for prevention and treatment of
cancer)

IT Antitumor agents
(ovary; therapeutic combination of **ascorbate** with
lysine or arginine for prevention and treatment of cancer)

IT Antitumor agents
(skin; therapeutic combination of **ascorbate** with
lysine or arginine for prevention and treatment of cancer)

IT Antitumor agents
(small intestine; therapeutic combination of **ascorbate** with
lysine or arginine for prevention and treatment of cancer)

IT Intestine, neoplasm
(small, inhibitors; therapeutic combination of **ascorbate** with
lysine or arginine for prevention and treatment of cancer)

IT Antitumor agents
(stomach; therapeutic combination of **ascorbate** with
lysine or arginine for prevention and treatment of cancer)

IT Drug delivery systems
(suppositories; therapeutic combination of **ascorbate** with
lysine or arginine for prevention and treatment of cancer)

IT Drug delivery systems
(tablets; therapeutic combination of **ascorbate** with
lysine or arginine for prevention and treatment of cancer)

IT Antitumor agents
(testis; therapeutic combination of **ascorbate** with
lysine or arginine for prevention and treatment of cancer)

IT Carotenes, biological studies
Trace elements, biological studies
Vitamins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(therapeutic combination of **ascorbate** with **lysine**
or arginine for prevention and treatment of cancer)

IT 50-81-7, Ascorbic acid, biological studies
56-40-6D, Glycine, chromium and molybdenum complexes
56-87-1, L-Lysine, biological studies 58-56-0,
Pyridoxine hydrochloride 58-85-5, Biotin 59-02-9,
D-..alpha..-Tocopherol 59-30-3, Folic acid, biological studies
59-67-6, Niacin, biological studies 67-03-8, Thiamine
hydrochloride 67-97-0, Cholecalciferol 68-19-9,
Cyanocobalamin 83-88-5, Riboflavin, biological studies
87-89-8, Inositol 98-92-0, Niacinamide
119-13-1, .delta.-Tocopherol 127-40-2, Lutein 137-08-6
137-66-6, Ascorbyl Palmitate 147-85-3, L-
Proline, biological studies 148-03-8, .beta.-Tocopherol
303-98-0, Coenzyme Q10 432-70-2, .alpha.-Carotene
472-70-8, Kryptoxanthin 541-15-1, L-Carnitine 657-27-2
, L-Lysine hydrochloride 1119-34-2, L-Arginine hydrochloride
3211-76-5, L-Selenomethionine 5743-27-1, Calcium
Ascorbate 7048-04-6, L-Cysteine hydrochloride monohydrate
7235-40-7, .beta.-Carotene 7439-96-5D, Manganese,

chelates 7439-98-7D, Molybdenum, glycinate complexes 7440-09-7, Potassium, biological studies 7440-47-3D, Chromium, glycinate complexes 7616-22-0, .gamma.-Tocopherol 7693-13-2, Calcium citrate 7757-93-9, Dicalcium Phosphate 7779-25-1, Magnesium citrate 13479-54-4, Copper glycinate 14281-83-5, Zinc glycinate 14451-00-4, Iron fumarate 14783-68-7 15431-40-0, Magnesium Ascorbate 35947-07-0, Calcium glycinate 174882-69-0, Pycnogenol

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic combination of ascorbate with lysine or arginine for prevention and treatment of cancer)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Bio Nutritional Health Service; GB 2268871 A 1994 HCAPLUS
- (2) Bostom, A; PHARMACOTHERAPY 1995, V15(4), P458 MEDLINE
- (3) Dioguardi, F; US 5198465 A 1993 HCAPLUS
- (4) Dzau, V; US 5891459 A 1999 HCAPLUS
- (5) Health Now Inc; EP 0891771 A 1999 HCAPLUS
- (6) Katz, E; JOURNAL OF ORTHOMOLECULAR MEDICINE 1996, V11/3, P173
- (7) Novo Med Ag; DE 3440090 A 1986 HCAPLUS
- (8) Otsuka Pharma Co Ltd; GB 2029220 A 1980 HCAPLUS
- (9) Paul, S; US 5626883 A 1997 HCAPLUS
- (10) Rath, M; US 5278189 A 1994 HCAPLUS
- (11) Rath, M; US 5650418 A 1997 HCAPLUS

L143 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:918845 HCAPLUS

DN 136:42851

TI Composition for the prevention of smooth muscle diseases comprising ascorbate, arginine and magnesium

IN Rath, Matthias

PA Neth.

SO Eur. Pat. Appl., 13 pp.

CODEN: EPXXDW

DT Patent

LA English

IC ICM A61K031-195

ICS A61K031-375; A61K033-14; A61P009-00; A61P011-00; A61P027-00

ICI A61K031-195, A61K031-375

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1163904	A1	20011219	EP 2000-112811	20000616
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2001003256	A	20020312	BR 2001-3256	20010613
	NO 2001003004	A	20011217	NO 2001-3004	20010615
	CN 1333020	A	20020130	CN 2001-124330	20010615
	JP 2002047183	A2	20020212	JP 2001-181658	20010615

PRAI EP 2000-112811 A 20000616

AB The invention relates to the use of biochem. substances for a compn. for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body like high blood pressure, asthma, glaucoma and tinnitus.

ST smooth muscle disease compn; ascorbate smooth muscle disease compn; arginine smooth muscle disease compn; magnesium compd smooth muscle disease compn

IT Flavonoids

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioflavonoids; compn. for prevention of smooth muscle diseases

comprising ascorbate, arginine and magnesium)
 IT Amino acids, biological studies
 Carotenes, biological studies
 Trace elements, biological studies
 Vitamins
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compn. for prevention of smooth muscle diseases comprising
 ascorbate, arginine and magnesium)
 IT Drug delivery systems
 (infusions; compn. for prevention of smooth muscle diseases comprising
 ascorbate, arginine and magnesium)
 IT Drug delivery systems
 (inhalants; compn. for prevention of smooth muscle diseases comprising
 ascorbate, arginine and magnesium)
 IT Drug delivery systems
 (injections; compn. for prevention of smooth muscle diseases comprising
 ascorbate, arginine and magnesium)
 IT Muscle, disease
 (smooth; compn. for prevention of smooth muscle diseases comprising
 ascorbate, arginine and magnesium)
 IT Drug delivery systems
 (suppositories; compn. for prevention of smooth muscle diseases
 comprising ascorbate, arginine and magnesium)
 IT Drug delivery systems
 (tablets; compn. for prevention of smooth muscle diseases comprising
 ascorbate, arginine and magnesium)
 IT 50-81-7, Ascorbic acid, biological studies
 52-90-4, L-Cysteine, biological studies 56-40-6D,
 Glycine, complex with transition metals 56-87-1, L-
 Lysine, biological studies 58-85-5, Biotin
 59-02-9, .alpha.-Tocopherol 59-30-3, Folic acid,
 biological studies 59-43-8, Thiamine, biological studies
 59-67-6, Niacin, biological studies 65-23-6,
 Pyridoxine 67-97-0, Cholecalciferol 68-19-9,
 Cyanocobalamin 74-79-3, L-Arginine, biological studies
 83-88-5, Riboflavin, biological studies 87-89-8,
 Inositol 98-92-0, Niacinamide 119-13-1,
 .delta.-Tocopherol 137-08-6, Calcium pantothenate
 137-66-6, Ascorbyl palmitate 147-85-3, L-
 Proline, biological studies 148-03-8, .beta.-Tocopherol
 303-98-0, Coenzyme q10 541-15-1, L-Carnitine
 3211-76-5, L-Selenomethionine 5743-27-1, Calcium
 ascorbate 7235-40-7, .beta.-Carotene 7439-96-5D
 , Manganese, chelates 7439-98-7D, Molybdenum, complex with
 glycine 7440-09-7D, Potassium, chelates 7440-47-3D,
 Chromium, complex with glycine 7616-22-0, .gamma.-Tocopherol
 7693-13-2, Calcium citrate 7757-93-9, Dicalcium
 phosphate 7779-25-1, Magnesium citrate 13479-54-4,
 Copper glycinate 14281-83-5, Zinc glycinate 14783-68-7
 15431-40-0, Magnesium ascorbate 35947-07-0,
 Calcium glycinate 174882-69-0, Pycnogenol
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compn. for prevention of smooth muscle diseases comprising
 ascorbate, arginine and magnesium)

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Bio Nutritional Health Service; GB 2268871 A 1994 HCPLUS
- (2) Bostom, A; Pharmacotherapy 1995, V15(4), P458 MEDLINE
- (3) Cooke, J; US 5891459 A 1999 HCPLUS
- (4) Dioguardi Francesco, S; US 5198465 A 1993 HCPLUS
- (5) Health Now Inc; EP 0891771 A 1999 HCPLUS
- (6) Otsuka Pharma Co Ltd; GB 2029220 A 1980 HCPLUS
- (7) Paul Stephen, M; US 5626883 A 1997 HCPLUS

(8) Rath, M; US 5650418 A 1997 HCAPLUS
 (9) Rath, M; Journal of Applied Nutrition 1996, V48/3(68-78)
 (10) Rath Matthias, W; US 5278189 A 1994 HCAPLUS

=> fil wpix
 FILE 'WPIX' ENTERED AT 08:41:37 ON 27 AUG 2002
 COPYRIGHT (C) 2002 THOMSON DERWENT

FILE LAST UPDATED: 23 AUG 2002 <20020823/UP>
 MOST RECENT DERWENT UPDATE 200254 <200254/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> SLART (Simultaneous Left and Right Truncation) is now
 available in the /ABEX field. An additional search field
 /BIX is also provided which comprises both /BI and /ABEX <<<

>>> The BATCH option for structure searches has been
 enabled in WPINDEX/WPIDS and WPIX <<<

>>> PATENT IMAGES AVAILABLE FOR PRINT AND DISPLAY <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,
 SEE <http://www.derwent.com/dwpi/updates/dwpicov/index.html> <<<

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
 PLEASE VISIT:

http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
 GUIDES, PLEASE VISIT:
http://www.derwent.com/userguides/dwpi_guide.html <<<

=> d all abeq tech abex tot

L188 ANSWER 1 OF 5 WPIX (C) 2002 THOMSON DERWENT

AN 2002-489753 [52] WPIX

DNC C2002-139000

TI Composition useful for lowering plasma concentration of lipoprotein, e.g. .
 in cardiovascular diseases, comprising ascorbic acid,
 niacin, lysine, proline or their salts.

DC B05

IN RATH, M

PA (RATH-I) RATH M

CYC 96

PI WO 2002028379 A2 20020411 (200252)* EN 21p A61K031-00 <--
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
 NL OA PT SD SE SL SZ TR TZ UG ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU
 SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AU 2002011452 A 20020415 (200254) A61K031-00 <--

US 2002094996 A1 20020718 (200254) A61K031-455 <--

ADT WO 2002028379 A2 WO 2001-US31203 20011003; AU 2002011452 A AU 2002-11452
 20011003; US 2002094996 A1 Provisional US 2000-237186P 20001003, US
 2001-970609 20011003

FDT AU 2002011452 A.Based on WO 200228379

PRAI US 2000-237186P 20001003; US 2001-970609 20011003

IC ICM A61K031-00; A61K031-455

ICS A61K031-198; A61K031-375; A61K031-401

AB WO 200228379 A UPAB: 20020815

NOVELTY - A composition (I) of biochemical substances comprises

ascorbic acid (II), niacin (III),
lysine (IV), proline (V) or their salts.

ACTIVITY - Cardiant; Antiarteriosclerotic; Antidiabetic;
Cerebroprotective; Vasotropic.

MECHANISM OF ACTION - None given in the source material.

USE - (I) Is used for treating diseases associated with a high level lipoprotein in plasma (claimed), e.g. myocardial infarction, stroke, restenosis or bypass stenosis, or ischemic heart diseases, arteriosclerosis, cerebrovascular diseases, carotid sclerosis and diabetes. (I) Is also used for correcting the dysfunction of hepatocyte metabolism.

ADVANTAGE - (I) Lowers the plasma concentration by at least 4 (preferably 8, especially 12)% of a lipoprotein selected from Lp(a), total cholesterol, LDL-cholesterol, triglycerides, low density lipoprotein or homocysteine in a mammal (preferably human) and thus reduces the risk of cardiovascular diseases.

In a test, the lowering of the plasma concentration over a the duration of 12 weeks indicated the therapeutic potential of (I) in controlling chronic elevation of lipoproteins in human.

Dwg.0/2

FS

CPI

FA

AB; DCN

MC

CPI: B03-A; B03-B; B03-C; B03-D; B03-E; **B03-F**; B03-G; B03-H;
B05-A03; B05-B01D; B05-B02A3; B06-A01; B06-D09; B06-F03; B07-D03;
B07-D04C; B10-A06; B10-A17; B10-A22; B10-B01B; B10-B02D; B10-B02J;
B10-C04D; B10-E04A; B14-F01B; B14-F01D; B14-F01G; B14-F02; B14-F06;
B14-F07; B14-N12; B14-N16; B14-S04

TECH

UPTX: 20020815

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Composition: (I) comprises: ascorbic acid, niacin (nicotinic acid and/or niacin amide), lysine (lysine hydrochloride), proline (proline hydrochloride), ascorbyl palmitate, beta-, gamma-, delta-tocopherol-mix, beta-carotene, biotin, calcium ascorbate, calcium glycinate, carotenoid mix, cholecalciferol, chromium glycinate, citrus bioflavonoids, coenzyme Q10, copper glycinate, cyanocobalamin, d-alpha-tocopherol, d-calcium pantothenate, dicalcium phosphate, folic acid, inositol, L-arginine, L-carnitine, L-cysteine, L-lysine, L-proline, L-selenomethionine, magnesium ascorbate, magnesium glycinate, manganese chelate, molybdenum glycinate, potassium chelate, pycnogenol, pyridoxine, riboflavin, thiamine and zinc glycinate.

ABEX

ADMINISTRATION - (I) Is administered orally, nasally, parenterally, topically or transdermally in a dosage of about 10 - 200 (preferably 50)%, in the form of tablets, pills, injections, infusions, inhalations, suppositories (claimed).

EXAMPLE - A composition comprised (mg) **ascorbic acid** (1580), **ascorbyl palmitate** (620), beta-, gamma-, delta-tocopherol-mix (22), beta-carotene (999 mcg), biotin (165 mcg), calcium **ascorbate** (1050), calcium glycinate (35), carotenoid-mix (50 mcg) (alpha-carotene, lutein, zea-cryptoxanthin), cholecalciferol (3.3 mcg), chromium glycinate (10 mcg), citrus bioflavonoid (550), coenzyme Q 10 (7), copper glycinate (330 mcg), cyanocobalamin (20 mcg), d-alpha-tocopherol (154), d-calcium pantothenate (90), dicalcium phosphate (15), folic acid (490 mcg), inositol (35), L-arginine (40), L-carnitine (135), L-cysteine (35), L-lysine (110), L-proline (110), L-selenomethionine (20 mcg), magnesium **ascorbate** (1050), magnesium glycinate (40 mcg), manganese chelate (1300 mcg), molybdenum glycinate (4 mcg), **niacin** (60), **niacinamide** (335), potassium chelate (20), pycnogenol (7), pyridoxine (20), riboflavin (7), thiamine (7), zinc glycinate (7). The prepared composition was administered to 14 patients. Various clinical parameters were recorded before the administration of the composition.

Blood samples were collected via venipuncture at the beginning of the study and plasma levels of various lipoproteins were monitored. The average plasma level of Lp(a) was 71 mg/dl, total cholesterol level was 293 mg/dl, LDL-cholesterol level was 195 mg/dl and triglyceride level was 193 mg/dl. The patients received the composition for a period of 3 months. At the end of the 3 months blood samples were again collected and plasma concentrations of various lipoproteins were monitored. The result showed that the patients after therapeutic administration of the composition had led to the following average decrease in plasma levels of 1) Lp(a) from 71 - 64 mg/dl, a decrease of 13%; 2) total cholesterol from 293 - 252 mg/dl, a decrease of 14%; 3) LDL-cholesterol from 195 - 176 mg/dl, a decrease of 10%; and 4) triglyceride from 193 - 151 mg/dl, a decrease of 22%.

L188 ANSWER 2 OF 5 WPIX (C) 2002 THOMSON DERWENT
 AN 2002-418680 [45] WPIX
 DNC C2002-118245
 TI Ascorbate composition, useful for treating cancer.
 DC B03-B05
 IN RATH, M
 PA (RATH-I) RATH M
 CYC 25
 PI EP 1195159 A1 20020410 (200245)* EN 12p A61K031-195 <--
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI
 ADT EP 1195159 A1 EP 2000-121950 20001009
 PRAI EP 2000-121950 20001009
 IC ICM A61K031-195
 ICS A61K031-375; A61P035-00
 ICI A61K031-195, A61K031:375
 AB EP 1195159 A UPAB: 20020717

NOVELTY - An ascorbic acid composition is new.

DETAILED DESCRIPTION - A composition comprises: **ascorbic acid** (2180 mg), **ascorbyl palmitate** (620 mg), **calcium ascorbate** (2000 mg), **magnesium ascorbate** (2000 mg), **biotin** (0.065 mg), **vitamin B1** (7 mg), **vitamin B2** (7 mg), **niacin** (10 mg), **niacinamide** (35 mg), **vitamin B5** (40 mg), **vitamin B6** (18 mg), **vitamin B12** (0.05 mg), **vitamin D3** (130 IU), **vitamin A** (4165 IU), **vitamin E** (330 IU), **folic acid** (0.49 mg), **L-proline** (560 mg), **L-lysine hydrochloride** (4010 mg), **L-carnitine** (35 mg), **L-arginine** (790 mg), **L-cysteine hydrochloride monohydrate** (35 mg), **calcium** (535 mg), **magnesium** (290 mg), **potassium** (20 mg), **zinc** (7 mg), **manganese** (1.3 mg), **copper** (0.33 mg), **selenium** (0.02 mg), **chromium** (0.01 mg), **molybdenum** (0.004 mg), **inositol** (35 mg), **coenzyme Q10** (7 mg), **phosphorus** (15 mg), **pycnogenol** (7 mg), **citrus bioflavonoids** (1150 mg), **beta** -, **gamma** and **delta** -**tocopherol** (22 mg), **alpha** -**carotene**, **lutein**, **zea-kyptoxanthin** (0.125 mg) and **iron** (10 mg).

INDEPENDENT CLAIMS are also included for:

(1) a composition comprising an **ascorbate** and an **arginine** compound; and

(2) a composition comprising an **ascorbate** and a **lysine** compound

ACTIVITY - Cytostatic.

MECHANISM OF ACTION - None given in the source material.

USE - The composition is useful for treating cancer, especially **breast**, **ovarian**, **cervical**, **testicular**, **esophageal**, **stomach**, **duodenal**, **intestinal**, **lung** and **brain** cancer and **melanoma** (claimed).

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B03-A; B03-B; B03-C; B03-D; B03-E; **B03-F**; B03-G; B03-H;
 B03-K; B03-L; B04-B04L; B04-L02; B05-A01A; B05-A01B; B05-A02;
 B05-A03A; B05-A03B; B05-B02A3; B06-F03; B07-A02A; B07-D04; B10-A22;
 B10-B02C; B10-E04A; B14-H01

ABEX

ADMINISTRATION - The composition can be administered either orally, parenterally, by inhalation or rectally. The daily recommended dose of the composition ranges between 50 mg to 500,00 mg. The composition can be in the form of tablets, pills, injections, infusions, inhalations or suppositories.

EXAMPLE - A patient presenting with esophageal cancer was treated over 3 months with 33 cobalt radiation treatments which were not effective. After 6 weeks on the novel composition, the tumor growth was halted and the patient had some weight gain. After a further 2 months of treatment, the tumor was readily decreasing in size and lung metastases had disappeared.

L188 ANSWER 3 OF 5 WPIX (C) 2002 THOMSON DERWENT
 AN 2002-091746 [13] WPIX
 DNC C2002-028525
 TI Use of biochemical substance for the treatment of smooth muscle diseases e.g. asthma, glaucoma, tinnitus and high blood pressure comprises vitamins, **amino acids** and trace elements.
 DC B05
 IN **RATH, M**
 PA (RATH-I) RATH M; (RATT-I) RATT M
 CYC 35
 PI EP 1163904 A1 20011219 (200213)* EN 13p A61K031-195 <--
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI
 AU 2001051942 A 20011220 (200213) A61K031-375 <--
 CA 2350713 A1 20011216 (200213) EN A61K031-375 <--
 NO 2001003004 A 20011217 (200213) A61K045-00
 SK 2001000823 A3 20020107 (200213) A61K031-195 <--
 ZA 2001004931 A 20020227 (200223) 13p A61K000-00
 BR 2001003256 A 20020312 (200226) A61K031-195 <--
 JP 2002047183 A 20020212 (200227) 8p A61K031-375 <--
 CN 1333020 A 20020130 (200231) A61K033-14
 CZ 2001002178 A3 20020417 (200231) A61K031-195 <--
 KR 2001113499 A 20011228 (200240) A61K031-375 <--
 ADT EP 1163904 A1 EP 2000-112811 20000616; AU 2001051942 A AU 2001-51942
 20010615; CA 2350713 A1 CA 2001-2350713 20010615; NO 2001003004 A NO
 2001-3004 20010615; SK 2001000823 A3 SK 2001-823 20010613; ZA 2001004931 A
 ZA 2001-4931 20010615; BR 2001003256 A BR 2001-3256 20010613; JP
 2002047183 A JP 2001-181658 20010615; CN 1333020 A CN 2001-124330
 20010615; CZ 2001002178 A3 CZ 2001-2178 20010615; KR 2001113499 A KR
 2001-33746 20010615
 PRAI EP 2000-112811 20000616
 IC ICM A61K000-00; **A61K031-195; A61K031-375; A61K033-14;**
 A61K045-00
 ICS **A61K031-015; A61K031-047; A61K031-122;**
A61K031-198; A61K031-205; A61K031-355;
A61K031-4188; A61K031-4415; A61K031-455;
A61K031-51; A61K031-525; A61K031-59;
A61K031-592; A61K031-714; A61K033-06; A61K033-24;
A61K033-32; A61K033-42; A61K035-78; A61P009-00; A61P009-12;
A61P011-00; A61P011-06; A61P021-02; A61P027-00; A61P027-06;
A61P027-16
 ICI A61K031-195, A61K031:375
 AB EP 1163904 A UPAB: 20020226
 NOVELTY - Use of a biochemical substance for the prevention and treatment of health conditions caused by constrictions of smooth muscle cells in organs of human body, comprises vitamins, **amino acids** and trace elements (preferably **ascorbic acid** or its **ascorbate salts** or mixture).
 ACTIVITY - Antiasthmatic; ophthalmological; hypotensive; antianginal; vasotropic.

A composition of biochemical substances comprising (mg) ascorbic acid (680), ascorbyl palmitate (620), beta-, gamma-, delta-tocopherol-mix (22), beta-carotene (1665 IU), biotin (65 micro g), calcium ascorbate (1050), calcium citrate (200), calcium glycinate (35), carotinoid-Mix (alpha-carot, Lutein, Zea-, Kryptoxanthin) (50 micro g), cholecalciferol (130 IU), chromium glycinate (10 micro g), citrus bioflavonoid (650), Q10 (coenzyme) (7), copper glycinate (330 micro g), cyanocobalamin (20 micro g), d-alpha-tocopherol (230 IU), d-calcium pantothenate (40), dicalcium phosphate (15), folic acid (90 micro g), inositol (35) and/or L-arginine (790), L-carnitine (35), L-cysteine (35), L-lysine (110), L-proline (110), L-selenomethionine (20 micro g) and/or magnesium ascorbate (1050), magnesium citrate (400), magnesium glycinate (40), manganese chelate (1300 micro g), molybdenum glycinate (4 micro g), niacin (10), niacinamid (35), potassium chelate (20), pycnogenol (7), pyrodoxine (10), riboflavin (7), thiamine (7) and zinc glycinate (7) was prepared. The composition was tested in a prospective clinical study with eight asthma patients. The patients received the composition of biochemical substances as a daily dosage for 4 months. At the beginning and at the end of the study the lung volume was measured in each patient. The lung volume (ml) measured graphically at the beginning/at the end of the study was: approx. 2000/ approx. 2500 - 3000 (for the first patient), 2000/ approx. close to 2500 (for the second patient), approx. 3500 - 4000/4000 (for the third patient), approx. close to 2500/3000 (for the fourth patient), 3000/ approx. above 3500 (for the fifth patient), 2000/ approx. 2000 - 2500 (for the sixth patient), approx. close to 1500/ approx. 2000 - 2500 (for the seventh patient), approx. 1000 - 1500/ approx. 2500 - 3000 (for the eighth patient). From the results obtained, it was concluded that during the study the asthma patients increased their lung volume on average by more than 20%. The most significant result of lung volume increase was much higher for those patients with the lowest base line values, which indicated that this therapy was particularly valuable with patients with severe asthma and a severe breathing impairment.

MECHANISM OF ACTION - None given in the source material.

USE - For the prevention and treatment of health conditions caused by constrictions of smooth muscle cells in organs of human body (claimed) e.g. high blood pressure, asthma, glaucoma, tinnitus, angina pectoris, impotence, other forms of obstructive lung diseases, other forms of increased eye pressure, pre-menstrual syndrome, infertility, spasms of the ureter, urethra, singultus, stomach cramps, spasms of the gall duct.

ADVANTAGE - The treatment with the compositions of biochemical substances leads to at least partly considerable relaxation of smooth muscle cells resulting in the increase of artery diameter of large arteries (e.g. aorta) lowering elevated blood pressure, increasing artery diameter of midsize arteries (e.g. coronary arteries) resulting in a decrease of angina pectoris, resulting in the increase of diameter of arterioles and capillaries (e.g. arteries of the ear) leading to improved hearing, relaxation of smooth muscle cells in lung bronchioles and alveoli leading to an increase of airway diameter following a decrease of asthma symptoms, the relaxation of canal systems of the eye resulting in an increase of diameter e.g. of tear ducts decreasing eye pressure leading to a decreased risk of glaucoma and blindness, the relaxation of smooth muscle cells in ovarian tubes and uterus resulting in relaxation of muscle tissue improving fertility and decreasing PMS symptoms, relaxation of smooth muscle cells in gall ducts, ureter and urethra increasing the diameter of ducts resulting in a decreased risk of cramps caused by gall stones or kidney stones.

Dwg.0/0

FS

CPI

FA

AB; DCN

MC

CPI: B03-D; B03-E; B03-F; B03-H; B04-L02; B05-A01B; B05-A03; B05-A03A; B05-B01D; B05-B01P; B06-D09; B06-D17; B06-F03; B07-A01;

B07-D04; B07-D12; B07-F01; B10-A06; B10-A17; B10-A22; B10-B01B;
 B10-B02; B10-B02B; B10-B02C; B10-B02J; B10-C02; B10-C04D; B10-E04A;
 B10-J01; B14-F01D; B14-F02; B14-F02B; B14-F02D2; B14-J05D; B14-K01A;
 B14-N02; B14-N03; B14-P02

TECH UPTX: 20020226

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Components: The biochemical substances are in combination with an arginine or magnesium compound. The arginine compound is arginine hydrochloride or its salt and/or mixture. The magnesium compound is magnesium or its salt and/or mixture. Preferred Composition: The arginine or magnesium components are combined together with at least one biochemical substance (A), irrespective of their dosages. (A) comprises (mg) **ascorbic acid** (680), **ascorbyl palmitate** (620), **beta-, gamma-, delta-tocopherol-mix** (22), **calcium ascorbate** (1050), **calcium citrate** (200), **calcium glycinate** (35), **citrus bioflavonoid** (650), **Q10 (coenzyme)** (7), **d-calcium pantothenate** (40), **dicalcium phosphate** (15), **inositol** (35), **L-arginine** (790), **L-carnitine** (35), **L-cysteine** (35), **L-lysine** (110), **L-proline** (110), **magnesium ascorbate** (1050), **magnesium citrate** (400), **magnesium glycinate** (40), **niacin** (10), **niacinamid** (35), **potassium chelate** (20), **pycnogenol** (7), **pyrodoxine** (10), **riboflavin** (7), **thiamine** (7) and **zinc glycinate** (7). (A) comprises (international units (IU)) **beta-carotene** (1665), **cholecalciferol** (130) and **d-alpha-tocopherol** (230). (A) includes (microg) **biotin** (65), **carotinoid-Mix** (**alpha-carot**, **Lutein**, **Zea-**, **Kryptoxanthin**) (50), **chromium glycinate** (10), **copper glycinate** (330), **cyanocobalamin** (20), **folic acid** (90), **L-selenomethionine** (20), **manganese chelate** (1300) and **molybdenum glycinate** (4). The individual components used irrespective of their amounts are more than 80% identical.

ABEX

ADMINISTRATION - The amount of individual components of (A) administered per day are 10 - 1000%. (A) is administered in the form of tablet, pill, injection, infusion, inhalation, suppository or other carrier and/or other devices of delivery.

EXAMPLE - No relevant example is given.

L188 ANSWER 4 OF 5 WPIX (C) 2002 THOMSON DERWENT

AN 1999-579624 [49] WPIX

DNC C1999-168597

TI Pharmaceutical composition for treatment of acne, used to reduce redness and blemishes associated with acne and conditions skin cells to reduce likelihood of further acne, without adverse effects.

DC B05

IN MURAD, H

PA (MURA-I) MURAD H

CYC 1

PI US 5962517 A 19991005 (199949)* 9p A61K031-715 <--

ADT US 5962517 A Provisional US 1997-36825P 19970131, US 1998-16800 19980130

PRAI US 1997-36825P 19970131; US 1998-16800 19980130

IC ICM A61K031-715

ICS A61K031-19; A61K031-34

AB US 5962517 A UPAB: 19991124

NOVELTY - Pharmaceutical composition for treatment of acne.

DETAILED DESCRIPTION - Pharmaceutical composition comprises:

(1) acne reduction component comprising 15-96 mg of at least one zinc compound or a vitamin A source in amount sufficient to reduce redness and blemishes associated with acne;

(2) at least one of burdock root, yellow dock root or catechin-based composition sufficient to facilitate maintenance of skin cells; and

(3) skin-cell conditioning component comprising transition metal other than zinc in amount sufficient to properly regulate the keratin and sebum production of skin cells to inhibit appearance of acne.

ACTIVITY - Anti-acne; skin repair; skin conditioner, skin

maintenance.

Fourteen panelists were subjected to global assessment of non-inflammatory and inflammatory lesions. All panelists exhibited grade two comedonal/inflammatory acne according to the Acne Grading Scale and were free from any skin disorders other than moderate acne. The patients were instructed to take two tablets in the morning and two in the evening, preferably with meals, and to record the administration time for the subsequent 6 weeks. Tablets contained (mg/tablet): **Vitamin E** succinate (63.1%, 158.5), **L-lysine** hydrochloride (80%; 156.3), **calcium ascorbate** (81%; 154.3), burdock root (150), yellow dock (125), **L-proline** (125), horsetail extract (silica; 100), **magnesium oxide** (60%; 83.3), **zinc ascorbate** (15%), **vitamin B6** (pyridoxine hydrochloride 82.7%; 15.1), grape seed extract (12.5), **vitamin B3** (niacin; 12.5), **beta carotene** (10), selenomethionine (0.5%; 10), biotin (1% 7.5), **vitamin B5** (91.7%; 6.8), **vitamin B2** (riboflavin; 6.3), **vitamin B1** (thiamine; 6.3), Chromemeate chromium GTF(RTM: chromium polynicotinate) (0.2%; 6.3), **vitamin A palmitate** (2.5) and **chromium picolinate** (12%; 0.1). In addition, panelists were advised not to use any new cosmetic or facial products, including acne medications, while in the study. Panelists returned after approximately 21 and 42 days for examination of the facial area to tabulate lesion counts and record the information on each panelist's score sheet. One panelist did not complete the study due to non-study reasons. Mean numbers of acne lesions at baseline and the midpoints and end of the study were 37, 22 and 16, respectively. The difference in number of lesions from baseline at midpoint and endpoint were neg. 15 and neg. 21, respectively, giving % differences between baseline and midpoint and endpoint respectively of neg. 36% and neg. 55%. Results demonstrated that daily use of the tablets resulted in a statistically significant decrease in number of acne lesions, without any panelist reporting adverse reactions.

USE - Used to treat acne (claimed). Used to reduce redness and blemishes associated with acne and condition skin cells to reduce likelihood of further acne.

ADVANTAGE - Avoids adverse side-effects.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B03-A; B03-D; **B03-F**; B04-A10; B05-A01B; B05-A03; B05-A03A; B05-A03B; B14-N17D

TECH UPTX: 19991124

TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - Preferred components: Transition metal is in form of transition metal complex, preferably complexed to a nitrogen-containing aromatic compound. Transition metal is a Group IVB, Group VB, Group VIB and/or Groups VIIB metal and the complex is present in an amount of 0.001-5 weight %.

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Acne-reduction component further comprises carotenoid component and/or **vitamin B6** source.

Vitamin A source comprises **Vitamin A** complexed with acetate or palmitate, carotenoid component comprises beta-carotene, **vitamin B6** source comprises pyridoxine, and zinc component comprises zinc complexed with **ascorbic acid** or **ascorbate**. **Vitamin A** source is **vitamin A** palmitate present in an amount of 0.005-5 weight %, beta-carotene present in an amount of 0.1-10 weight %, pyridoxine is pyridoxine present in an amount of 0.2-20 weight % and zinc component is **zinc ascorbate** present in an amount of 0.1-25 weight %. Composition further comprises **vitamin C** source (**ascorbic acid** or **ascorbate** (1-30 weight%)), horsetail extract, **vitamin B1** source (**thiamin**), **vitamin B2** source (**riboflavin**), **vitamin B3** source (**niacinamide**), **vitamin B5** source (**pantothenic acid**) and **vitamin E** source (**sulfate** or **succinate** **vitamin E** complex) all in amounts

sufficient to facilitate maintenance of skin cells. Catechin source (niacinamide), vitamin B5 source (pantothenic acid) and vitamin E source (sulfate or succinate vitamin E complex) all in amounts sufficient to facilitate maintenance of skin cells. Catechin-based composition comprises proanthanol or proanthocyanidin.

Composition comprises 1-30 weight % calcium ascorbate, 1-30 weight % burdock root, 1-30 weight % yellow dock root, 1-20 weight % horsetail root, 0.1-15 weight % catechin-based composition containing proanthocyanidin, 0.05-5 weight % niacinamide, 0.05-5 weight % pantothenic acid, 0.05-5 weight % riboflavin, 0.05-5 weight % thiamin and 1-30 weight % vitamin E succinate.

Composition further comprises amino acid component (L-lysine; L-proline), magnesium component (magnesium oxide), selenium component (selenium complexed to amino acid) and/or biotin in amounts sufficient to facilitate repair of skin damaged by acne. Composition comprises 1-30 weight % L-lysine hydrochloride + L-proline, 1-20 weight % magnesium oxide, 0.05-10 weight % L-selenomethionine and b 0.01-5 weight % biotin.

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred compositions: Compositions include pharmaceutically acceptable excipient or carrier.

ABEX

ADMINISTRATION - Administration is oral in the form of tablets or capsules containing 1-2,500 (400-2,000; 800-1,600) mg (claimed). Administration may be in 1-10 (4-8) doses per day. Administration may also be rectal, parenteral, intravenous, topical, transdermal, subcutaneous and intramuscular. Administration may be in conjunction with concurrent or subsequent treatment by at least an additional pharmaceutical composition used to treat acne or condition the skin including topical applications comprising benzoyl peroxide, erythromycin, clindamycin, tretinoin, vitamin E and/or vitamin A and its derivatives or an oral application comprising erythromycin, tetracycline, isotretinoin, vitamin C, vitamin D chaparral, dandelion root, licorice root, Echinacea, kelp, cayenne, sassafras, elder flowers, pantothenic acid, para-aminobenzoic acid, biotin, choline, inositol, folic acid, calcium, magnesium, potassium and/or vitamin A derivatives.

L188 ANSWER 5 OF 5 WPIX (C) 2002 THOMSON DERWENT

AN 1994-010568 [02] WPIX

DNC C1994-004285

TI Food (supplement) compsns - of proteinaceous and nutrient substances in eg capsule form to eg improve sexual potency.

DC B04 D13

IN STEPHAN, P M

PA (BION-N) BIO-NUTRITIONAL HEALTH SERVICES LTD

CYC 44

PI GB 2268871 A 19940126 (199402)* 48p A23L001-305

WO 9401006 A2 19940120 (199404) EN 49p A23L001-305

RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL OA PT SE
 W: AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG
 MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AU 9345099 A 19940131 (199422) A23L001-305

WO 9401006 A3 19940331 (199516) A23L001-305

ADT GB 2268871 A GB 1993-13858 19930705; WO 9401006 A2 WO 1993-GB1409
 19930705; AU 9345099 A AU 1993-45099 19930705; WO 9401006 A3 WO
 1993-GB1409 19930705

FDT AU 9345099 A Based on WO 9401006

PRAI GB 1992-14247 19920704

REP No-SR.Pub; DE 2505717; EP 102663; EP 259167; EP 302807; FR 2154397; FR
 2244468; FR 2605854

IC ICM A23L001-305

ICS A23L001-302; A23L001-304

AB GB 2268871 A UPAB: 19940223

Food comprises (I) at least one protein, peptide, polypeptide or amino acid and (II) at least one vitamin, mineral or trace element.

(I) is 10 power(-8)g to 10g/RDA of (II).

Compsns. are in discrete portions, esp. tablets, lozenges or capsules, esp. chewable, suckable, water-soluble or slow-release tablets or lozenges, or are in gum, powder, soln. or liq. suspension form. (I) is pref. at least one gland, organ, blood vessel, muscle or skin extract, esp. obtd. by filtration or other purifcn. from foetal or adult non-human non-bovine tissue. It is esp. RNA (esp. at 10-50 mg per RDA) and/or ATP (esp. at 1-10mg per RDA). (I) pref. includes at least one of vitamin A (esp. at 0.5-1.0 mg, vitamin B, (0.5-1.5 mg), vitamin B2 (0.5-1.7 mg), vitamin B3 (15-19 mg), vitamin B6 (1.0-2.2 mg). vitamin B12 (2.0-3.0 mcg), folic acid (300-400 mcg), pantothenic acid (5.0-7.0 mg), biotin (150.0-200.0 mcg), choline, inositol, para-aminobenzoic acid, vitamin C (30.0-60.0 mg), vitamin D (2.5-10.0 mcg of vitamin D3), vitamin E (5.0-20 mg), Ca (800mg), P (800mg), Mg (300(300-400)(350)mg), Fe (18 mg), I (150 mcg), F (1.5(1.5-4.0)mg), Zn (15.0 mg), Cu(2.0-3.0 mg), Mn (2.5-5.0 (4)mg), Se (50(50-200) (60) mcg), Cr (50(50-200)(60) mcg), B((1-5(2) mg) and/or Mo (150(150-500)mcg)). (II) includes aminoacid (3), esp. Ile, Phe, Leu, Thr, Lys, Try, Met, Val, Ala, Gly, Arg, Pro, Asp, Ser, Cys, Tyr or Glu.

USE/ADVANTAGE - Compsns. improve sexual potency, skin health, vigour and **vitality**, prostate or menopause problems, rheumatism or arthritis, immune system, stress, mental function, heart functions and circulation. Compsns. may be administered as tablets, pills, lozenges or capsules or in liq. form and are not medicines.

Dwg.0/0

FS CPI

FA AB

MC CPI: D03-H01T2

=> d his

(FILE 'HOME' ENTERED AT 06:51:22 ON 27 AUG 2002)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 06:51:50 ON 27 AUG 2002

E RATH M/AU

L1 62 S E3-E7,E14,E15

L2 8 S L1 AND (?CHOLESTER? OR ?LIPOPROTEIN?)
E US2000-237186/AP,PRN

L3 1 S E5

E WO2001-US31203/AP,PRN

L4 1 S E3

L5 1 S L3,L4

L6 1 S L1,L2 AND L5
SEL RN

FILE 'REGISTRY' ENTERED AT 06:55:51 ON 27 AUG 2002

L7 44 S E1-E44

L8 3 S 50-81-7 OR 10504-35-5 OR 62624-30-0

L9 845 S (50-81-7 OR 10504-35-5 OR 62624-30-0)/CRN

L10 1 S L7 AND L8

L11 2 S L7 AND L9

L12 4 S L7 AND OC4/ES

L13 7 S L9 AND (CA OR MG)/ELS AND 2/NC NOT (IDS OR MXS OR PMS OR MNS)

L14 5 S L13 NOT (45CA OR KAPPA)
 L15 840 S L9 NOT L8,L10-L12,L14
 L16 28 S C22H38O7/MF AND OC4/ES
 L17 15 S L16 AND ASCORBIC ACID
 L18 7 S L17 AND 6
 L19 6 S L18 AND 1/NR
 L20 4 S L19 AND HEXADECANOATE
 L21 2 S L20 NOT (ION OR GAMMA)
 L22 2 S 59-67-6 OR 98-92-0
 L23 824 S (59-67-6 OR 98-92-0)/CRN
 L24 2 S L7 AND L22,L23
 L25 3 S 56-87-1 OR 923-27-3 OR 70-54-2
 L26 2112 S (56-87-1 OR 923-27-3 OR 70-54-2)/CRN
 L27 2 S L7 AND L25,L26
 L28 3 S 147-85-3 OR 344-25-2 OR 609-36-9
 L29 229 S (147-85-3 OR 344-25-2 OR 609-36-9)/CRN
 L30 2 S L7 AND L28,L29
 L31 34 S L7 NOT L8,L10,L11,L12,L14,L21,L22,L24,L25,L27,L28,L30
 L32 1 S 57-88-5
 L33 1 S 6027-13-0
 L34 2 S (D-HOMOCYSTEINE OR DL-HOMOCYSTEINE)/CN
 L35 32 S L31 NOT L32-L34
 L36 1 S (.BETA.-TOCOPHEROL)/CN
 L37 1 S (.GAMMA.-TOCOPHEROL)/CN
 L38 1 S (.DELTA.-TOCOPHEROL)/CN
 L39 1 S .BETA.-CAROTENE/CN
 L40 1 S BIOTIN/CN
 L41 1 S CALCIUM GLYCINATE/CN
 L42 1 S COENZYME Q10/CN
 L43 1 S COPPER GLYCINATE/CN
 L44 1 S CYANOCOBALAMIN/CN
 L45 1 S D-.ALPHA.-TOCOPHEROL/CN
 L46 1 S CALCIUM PANTOTHENATE/CN
 L47 5 S 79-83-4/CRN AND CA/ELS AND 2/NC
 L48 3 S L47 NOT (MXS OR IDS)/CI
 L49 1 S DICALCIUM PHOSPHATE/CN
 L50 1 S FOLIC ACID/CN
 L51 2 S INOSITOL/CN
 L52 1 S L-ARGININE/CN
 L53 1 S L-CARNITINE/CN
 L54 1 S L-CYSTEINE/CN
 L55 1 S L-SELENOMETHIONINE/CN
 L56 13 S 7664-38-2/CRN AND CA/ELS AND 2/NC NOT (IDS OR PMS OR MNS OR M
 L57 12 S L56 NOT 45CA
 L58 1 S L31 AND MG/ELS
 L59 1 S PYCNOGENOL/CN
 L60 1 S PYRIDOXINE/CN
 L61 1 S RIBOFLAVIN/CN
 L62 1 S THIAMINE/CN
 L63 1 S ZINC GLYCINATE/CN
 L64 0 S (148-03-8 AND 7616-22-0 AND 119-13-1)/CRN
 L65 38 S L36-L46,L48-L55,L57-L63
 L66 9 S L35 NOT L65
 SEL RN 1 6 8
 L67 3 S E45-E47
 L68 2 S C4H8CRN204/MF
 L69 1 S C4H8MGN204/MF
 L70 0 S C4H8MON204/MF
 L71 6 S C4H8N2O4ZN/MF
 L72 1 S GLYCINE/CN
 L73 1 S C4H8CAN204/MF
 L74 41 S 56-40-6/CRN AND (CA OR CR OR CU OR MG OR MO OR ZN)/ELS
 L75 11 S L74 AND 2/NC

L76 4 S L75 NOT (CL/ELS OR COMPD)
 L77 24 S C4H8CUN2O4/MF
 L78 17 S L77 AND GLYCIN?
 L79 15 S L78 AND 2/NR
 L80 11 S L79 NOT D/ELS
 SEL RN 1 6 9 10 11
 L81 5 S E48-E52
 L82 55 S L65, L67-L69, L71, L73, L76, L81
 L83 6 S L66 NOT L82
 L84 1 S L83 AND C6/ES
 L85 4 S L83 NOT L72, L84

FILE 'HCAPLUS' ENTERED AT 07:34:44 ON 27 AUG 2002

L86 46509 S L8, L10, L11, L12, L14, L21
 L87 90884 S ASCORBIC ACID OR VITAMIN(S)C
 L88 94543 S L86, L87
 L89 3119 S L15
 L90 95752 S L88, L89
 L91 13273 S L22 OR L24
 L92 35062 S NICOTINIC ACID OR NIACIN AMIDE OR NIACINAMIDE OR NIACIN OR VI
 761 S 3 PYRIDINECARBOXAMIDE OR PYRIDINE 3 CARBOXYLIC ACID
 L93 882 S 3 PYRIDINECARBOXYLIC ACID
 L94 7 S 3 AMINOCARBONYLPYRIDINE
 L95 20 S 3 CARBAMOYLPYRIDINE
 L96 9 S 3 AMIDOPYRIDINE
 L97 53 S 3 PYRIDINE CARBOXYLIC ACID
 L98 1250 S L23
 L100 38515 S L91-L99
 L101 35891 S L25 OR L27
 L102 9829 S L26
 L103 86562 S LYSINE
 L104 93564 S L101-L103
 L105 22331 S L28 OR L30
 L106 758 S L29
 L107 53725 S PROLINE
 L108 57057 S L105-L107
 L109 118 S L90 AND L100 AND L104 AND L108
 L110 118 S (L90 OR ASCORB?) AND L100 AND L104 AND L108
 L111 118 S L109, L110
 L112 90 S L111 AND L72
 L113 38 S L112 AND L85
 L114 97 S L111 AND L82
 L115 118 S L111-L114

FILE 'REGISTRY' ENTERED AT 07:47:07 ON 27 AUG 2002

L116 1 S CITRIC ACID/CN
 L117 6607 S 77-92-9/CRN
 L118 4998 S L117 AND 2/NC NOT (MXS OR MNS OR IDS OR PMS)/CI
 L119 4920 S L118 NOT COMPD
 L120 4416 S L119 AND NR>=1
 L121 504 S L119 NOT L120

FILE 'HCAPLUS' ENTERED AT 07:48:36 ON 27 AUG 2002

L122 27 S L116, L121 AND L111
 L123 118 S L115, L122
 L124 3 S L1 AND L123
 L125 34 S L123 AND PHARMACEUT?/SC, SX
 L126 17 S L123 AND PHARMACOL?/SC, SX
 L127 55 S L123 AND (FOOD? OR NUTRI? OR FEED?)/SC, SX
 L128 3 S L6, L124 AND L125-L127
 L129 78 S L125-L127 NOT L128
 L130 37 S L123 NOT L128, L129
 L131 13 S L129 AND (L32 OR ?CHOLESTER?)

L132 1 S L129 AND (L33 OR L34 OR HOMOCYST?)
 L133 1 S L129 AND (LIPOPROTEIN? OR LPA OR LP A)
 L134 2 S L129 AND TRIGLYCER?
 L135 0 S L129 AND LDL
 L136 0 S L129 AND LOW DENSITY (S) LIPOPROTEIN
 L137 0 S L129 AND LOW DN (S) LIPOPROTEIN
 L138 0 S L129 AND LOW DEN? (S) LIPOPROTEIN
 L139 0 S L129 AND LOW D (S) LIPOPROTEIN
 L140 0 S L129 AND LOW D (L) LIPOPROTEIN
 L141 16 S L131-L134
 L142 62 S L129 NOT L131-L141
 L143 3 S L128 AND L1-L6, L86-L115, L122-L142

FILE 'HCAPLUS' ENTERED AT 08:10:21 ON 27 AUG 2002

FILE 'WPIX' ENTERED AT 08:10:54 ON 27 AUG 2002
 E WO2002028379/PN

L144 1 S E3
 L145 734 S A61K031-375/IC, ICM, ICS
 L146 16681 S ASCORBIC ACID OR VITAMIN(S)C OR V330/M0, M1, M2, M3, M4, M5, M6 OR
 L147 3660 S (B03-F OR C03-F)/MC
 E ASCORBIC ACID/DCN
 E E4+ALL
 L148 90 S E2
 L149 1513 S E6
 L150 225 S E8
 L151 16963 S L145-L150
 L152 761 S A61K031-455/IC, ICM, ICS
 L153 4637 S L92-L98
 E NIACIN/DCN
 E E3+ALL
 L154 626 S E2 OR R00190/DCN
 L155 277 S E4
 L156 1684 S E6 OR 0678/DRN OR 0190/DRN
 L157 1086 S L151 AND L152-L156
 L158 435 S A61K031-198/IC, ICM, ICS
 E LYSINE/DCN
 E E17+ALL
 L159 93 S E2
 L160 2665 S E4 OR 1655/DRN
 L161 582 S E6
 E LYSINE/DCN
 E E6+ALL
 L162 271 S E2
 L163 244 S E4
 E LYSINE/DCN
 E E13+ALL
 L164 51 S E2
 L165 51 S E4
 L166 8470 S LYSIN?
 L167 121 S L157 AND L158-L166
 L168 167 S A61K031-401/IC, ICM, ICS
 E PROLINE/DCN
 E E3+ALL
 L169 1264 S E2 OR 1409/DRN
 L170 118 S E6
 L171 21 S E8
 L172 231 S E10
 L173 3534 S PROLIN?
 L174 55 S L167 AND L168-L173
 L175 19 S L174 AND A61K031/IC, ICM, ICS
 SEL DN AN 4 11 12 17 19
 L176 14 S L175 NOT E1-E11

L177 3 S RATH M?/AU AND L174
L178 3 S L144, L177
L179 11 S L176 NOT L178
SEL DN AN 4
L180 1 S L179 AND E12-E13
L181 4 S L178, L180
L182 36 S L174 NOT L175-L181
SEL DN AN 26
L183 1 S L182 AND E14-E15
L184 5 S L181, L183 AND L144-L183
L185 5 S L184 AND (AMINOACID OR AMINO ACID OR LYS OR ?LYSIN? OR ?LYSY?
L186 5 S L184, L185
L187 2 S L184 AND (AMINOACID OR AMINO ACID OR LYS OR ?LYSIN? OR ?LYSY?
L188 5 S L186, L187

FILE 'WPIX' ENTERED AT 08:41:37 ON 27 AUG 2002